JP2016507500A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016507500A5 JP2016507500A5 JP2015549742A JP2015549742A JP2016507500A5 JP 2016507500 A5 JP2016507500 A5 JP 2016507500A5 JP 2015549742 A JP2015549742 A JP 2015549742A JP 2015549742 A JP2015549742 A JP 2015549742A JP 2016507500 A5 JP2016507500 A5 JP 2016507500A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- administration
- compound
- human subject
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 208000007542 Paresis Diseases 0.000 claims 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 6
- 230000002496 gastric effect Effects 0.000 claims 6
- 229940123736 Decarboxylase inhibitor Drugs 0.000 claims 3
- 239000003954 decarboxylase inhibitor Substances 0.000 claims 3
- 229960003638 dopamine Drugs 0.000 claims 3
- 239000002207 metabolite Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 230000000699 topical effect Effects 0.000 claims 3
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 230000002411 adverse Effects 0.000 claims 2
- 230000008499 blood brain barrier function Effects 0.000 claims 2
- 210000001218 blood-brain barrier Anatomy 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 210000000105 enteric nervous system Anatomy 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- 206010000060 Abdominal distension Diseases 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 241000792859 Enema Species 0.000 claims 1
- 206010021518 Impaired gastric emptying Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 230000004596 appetite loss Effects 0.000 claims 1
- 208000024330 bloating Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229960004205 carbidopa Drugs 0.000 claims 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical group NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000007920 enema Substances 0.000 claims 1
- 229940095399 enema Drugs 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 208000019017 loss of appetite Diseases 0.000 claims 1
- 235000021266 loss of appetite Nutrition 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 239000006191 orally-disintegrating tablet Substances 0.000 claims 1
- 235000015927 pasta Nutrition 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261745734P | 2012-12-24 | 2012-12-24 | |
| US61/745,734 | 2012-12-24 | ||
| PCT/US2013/076733 WO2014105655A1 (en) | 2012-12-24 | 2013-12-19 | Methods for treating gi tract disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017108370A Division JP6437593B2 (ja) | 2012-12-24 | 2017-05-31 | Ｇｉ管障害を治療するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016507500A JP2016507500A (ja) | 2016-03-10 |
| JP2016507500A5 true JP2016507500A5 (enExample) | 2017-02-09 |
| JP6154025B2 JP6154025B2 (ja) | 2017-06-28 |
Family
ID=51021982
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015549742A Active JP6154025B2 (ja) | 2012-12-24 | 2013-12-19 | Ｇｉ管障害を治療するための方法 |
| JP2017108370A Active JP6437593B2 (ja) | 2012-12-24 | 2017-05-31 | Ｇｉ管障害を治療するための方法 |
| JP2018213361A Pending JP2019048848A (ja) | 2012-12-24 | 2018-11-14 | Ｇｉ管障害を治療するための方法 |
| JP2021021155A Pending JP2021088575A (ja) | 2012-12-24 | 2021-02-12 | Ｇｉ管障害を治療するための方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017108370A Active JP6437593B2 (ja) | 2012-12-24 | 2017-05-31 | Ｇｉ管障害を治療するための方法 |
| JP2018213361A Pending JP2019048848A (ja) | 2012-12-24 | 2018-11-14 | Ｇｉ管障害を治療するための方法 |
| JP2021021155A Pending JP2021088575A (ja) | 2012-12-24 | 2021-02-12 | Ｇｉ管障害を治療するための方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (7) | US9132134B2 (enExample) |
| EP (1) | EP2934540B1 (enExample) |
| JP (4) | JP6154025B2 (enExample) |
| CN (1) | CN104884064A (enExample) |
| AU (1) | AU2013370966A1 (enExample) |
| BR (1) | BR112015015258A2 (enExample) |
| CA (2) | CA2893427C (enExample) |
| ES (1) | ES2955693T3 (enExample) |
| WO (1) | WO2014105655A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9107815B2 (en) * | 2008-02-22 | 2015-08-18 | Allergan, Inc. | Sustained release poloxamer containing pharmaceutical compositions |
| AU2013370966A1 (en) * | 2012-12-24 | 2015-06-18 | Neurogastrx, Inc. | Methods for treating GI tract disorders |
| WO2015200369A1 (en) | 2014-06-24 | 2015-12-30 | Neurogastrx, Inc. | Prodrugs of metopimazine |
| US9695138B1 (en) | 2016-10-17 | 2017-07-04 | Acenda Pharma, Inc. | Phenothiazine derivatives and methods of use thereof |
| CN109053716B (zh) * | 2018-09-26 | 2021-01-08 | 暨明医药科技（苏州）有限公司 | 一种制备美托哌丙嗪的新工艺 |
| US10836757B1 (en) * | 2020-04-02 | 2020-11-17 | Neurogastrx, Inc. | Polymorphic forms of metopimazine |
| WO2022146970A1 (en) * | 2020-12-29 | 2022-07-07 | Neurogastrx, Inc. | Methods of metabolizing metopimazine and its salts |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1092476B (de) | 1958-04-24 | 1960-11-10 | Rhone Poulenc Sa | Verfahren zur Herstellung von Phenthiazinderivaten |
| BE786583A (fr) | 1971-07-21 | 1973-01-22 | Rhone Poulenc Sa | Nouveaux derives de la phenothiazine, leur preparation et les compositions qui les contiennent |
| IT1202370B (it) | 1976-07-12 | 1989-02-09 | Hoffmann La Roche | Soluzioni inietabili in cui l'atti vita' emolitica degli agenti di formazione di micelle naturali e' evitata mediante l'aggiunta di lipoidi e relativi prodotti |
| DE2914788A1 (de) | 1979-04-11 | 1980-10-16 | Nattermann A & Cie | Parenteral applizierbare, stabile arzneimittelloesungen mit entzuendungshemmender wirkung |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4412999A (en) | 1982-04-14 | 1983-11-01 | Merck & Co., Inc. | Anti-emetic esters of cyproheptadine-3-carboxylic acid and structurally related compounds |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| GB8424709D0 (en) | 1984-10-01 | 1984-11-07 | Minnesota Mining & Mfg | Azine redox dyes and leuco azine dyes |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4959217A (en) | 1986-05-22 | 1990-09-25 | Syntex (U.S.A.) Inc. | Delayed/sustained release of macromolecules |
| US4925678A (en) | 1987-04-01 | 1990-05-15 | Ranney David F | Endothelial envelopment drug carriers |
| US5080646A (en) | 1988-10-03 | 1992-01-14 | Alza Corporation | Membrane for electrotransport transdermal drug delivery |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5244925A (en) | 1987-12-18 | 1993-09-14 | Kabi Pharmacia Aktiebolag | Emulsion for parenteral administration |
| GB2228412B (en) | 1989-02-28 | 1993-04-14 | Syntex Inc | Nicardipine pharmaceutical composition for parenteral administration |
| IT1230881B (it) | 1989-06-20 | 1991-11-08 | Angeli Inst Spa | Derivati del r(-) 3-chinuclidinolo |
| US5167616A (en) | 1989-12-14 | 1992-12-01 | Alza Corporation | Iontophoretic delivery method |
| DK203990D0 (da) | 1990-08-24 | 1990-08-24 | Novo Nordisk As | Piperazinylderivater |
| US5225182A (en) | 1991-10-31 | 1993-07-06 | Sharma Yash P | Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system |
| US5434174A (en) | 1992-07-17 | 1995-07-18 | Eli Lilly And Company | Isoxazole derivatives for the treatment of irritable bowel syndrome |
| US5437291A (en) | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
| US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
| WO1997002043A1 (en) | 1995-06-30 | 1997-01-23 | Novo Nordisk A/S | Prevention of a disease having the characteristics of diabetes |
| GB9606076D0 (en) | 1996-03-22 | 1996-05-22 | Univ Birmingham | Diabetes treatment |
| US6756056B2 (en) * | 1997-04-08 | 2004-06-29 | Alan A. Rubin | Treatment of Parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa |
| US7098232B1 (en) | 1999-10-22 | 2006-08-29 | Athpharma Limited | Treatment and prevention of gastrointestinal disease using antagonists of partial agonists of 5HT1a receptors |
| EP1235561A2 (en) * | 1999-11-30 | 2002-09-04 | Panacea Biotec Limited | Fast dissolving composition with prolonged sweet taste |
| US20030176421A1 (en) | 1999-12-30 | 2003-09-18 | Watson John W. | Prokinetic agents for treating gastric hypomotility and related disorders |
| US6239122B1 (en) | 2000-01-05 | 2001-05-29 | Joy Ann Steele | Method of treatment of nausea, vomiting, and other disorders using estrogens |
| PL361875A1 (en) | 2000-11-15 | 2004-10-04 | Tap Pharmaceutical Products, Inc. | Treatment of anti-depression drug-induced sexual dysfunction with apomorphine |
| US20020108869A1 (en) | 2001-02-09 | 2002-08-15 | Alex Savtchenko | Device and technique for multiple channel patch clamp recordings |
| US20070129307A1 (en) | 2001-06-22 | 2007-06-07 | The University Of British Columbia | Insulin epitopes for the treatment of type 1 diabetes |
| GB2389791B (en) | 2002-04-30 | 2006-12-13 | Steven Gill | Implantable drug delivery pump |
| FR2845914B1 (fr) | 2002-10-18 | 2005-11-04 | Schwarz Pharma Lab | Compose antiemetique a desagregation rapide |
| US7618948B2 (en) | 2002-11-26 | 2009-11-17 | Medtronic, Inc. | Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA |
| WO2004062623A2 (en) | 2003-01-13 | 2004-07-29 | Dynogen Pharmaceuticals, Inc. | Method of treating functional bowel disorders |
| US20040172084A1 (en) | 2003-02-03 | 2004-09-02 | Knudson Mark B. | Method and apparatus for treatment of gastro-esophageal reflux disease (GERD) |
| JP2006520777A (ja) | 2003-03-17 | 2006-09-14 | ファイザー・プロダクツ・インク | Ｐｄｅ５阻害剤を用いる１型糖尿病の治療 |
| CA2521369A1 (en) | 2003-04-08 | 2004-10-28 | Progenics Pharmaceuticals, Inc. | The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome |
| US8815950B2 (en) * | 2003-08-29 | 2014-08-26 | Janssen Biotech, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| US7358271B2 (en) | 2003-09-05 | 2008-04-15 | Williamsburg Holdings Llc | Sulpiride pharmaceutical compositions |
| US20060287221A1 (en) | 2003-11-13 | 2006-12-21 | Novo Nordisk A/S | Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia |
| WO2006020930A2 (en) | 2004-08-12 | 2006-02-23 | Sapphire Therapeutics, Inc. | Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues |
| WO2006052626A2 (en) | 2004-11-03 | 2006-05-18 | The Board Of Regents Of The University Of Texas System | Dopamine 3 receptor agonist and antagonist treatment of gastrointestinal motility disorders |
| WO2006069276A2 (en) * | 2004-12-22 | 2006-06-29 | Janssen Pharmaceutica N.V. | TRICYCLIC ō-OPIOID MODULATORS |
| US20090054319A1 (en) | 2005-03-17 | 2009-02-26 | Microbia, Inc. | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders |
| US20070016262A1 (en) | 2005-07-13 | 2007-01-18 | Betastim, Ltd. | Gi and pancreatic device for treating obesity and diabetes |
| WO2007022531A2 (en) | 2005-08-19 | 2007-02-22 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| WO2008002971A2 (en) | 2006-06-29 | 2008-01-03 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| PL2136801T3 (pl) | 2007-03-30 | 2013-01-31 | Tioga Pharmaceuticals Inc | Agoniści kappa-opioidów do leczenia zespołu jelita drażliwego w postaci zmiennej i z dominującą biegunką |
| MX2009011577A (es) * | 2007-04-26 | 2010-03-10 | Craig A Aronchick | Composiciones y metodos para distribucion de domperidona a traves de la mucosa. |
| WO2008141074A1 (en) | 2007-05-10 | 2008-11-20 | Salk Institute For Biological Studies | Identification of compounds that protect against amyloid diseases |
| US7930033B2 (en) | 2007-08-17 | 2011-04-19 | Jianfeng Chen | Appendicular and rectal stimulator device for digestive and eating disorders |
| US20090326004A1 (en) | 2008-06-03 | 2009-12-31 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
| ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
| JP5756105B2 (ja) * | 2009-07-31 | 2015-07-29 | クレラ インコーポレイティッド | パーキンソン病の治療のための組成物および方法 |
| ES2437921T3 (es) | 2009-10-21 | 2014-01-15 | Wisconsin Alumni Research Foundation | Método para prevenir la diabetes tipo 1 |
| US8417465B2 (en) | 2009-11-04 | 2013-04-09 | Cfd Research Corporation | Synthetic microfluidic blood-brain barrier |
| CN102781424B (zh) * | 2010-03-04 | 2016-03-30 | 奥赖恩公司 | 左旋多巴、卡比多巴和恩他卡朋用于治疗帕金森病的应用 |
| US8329009B2 (en) | 2010-04-09 | 2012-12-11 | Molecular Devices, Llc | High throughput screening of ion channels |
| JP5860457B2 (ja) | 2010-06-18 | 2016-02-16 | アルトス・セラピューティクス・リミテッド・ライアビリティ・カンパニーＡｌｔｏｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｌｌｃ | Ｄ２アンタゴニスト、その合成方法および使用方法 |
| US20120053121A1 (en) | 2010-08-31 | 2012-03-01 | Nationwide Children's Hospital, Inc. | Administration of HB-EGF for the Protection of Enteric Neurons |
| US20120101089A1 (en) | 2010-10-26 | 2012-04-26 | Ashwani Agarwal | Anti-Emetic Substance |
| WO2013028909A1 (en) | 2011-08-25 | 2013-02-28 | Sova Pharmaceuticals, Inc. | Combination therapy for the treatment of sleep-related breathing disorders |
| FR2980976B1 (fr) | 2011-10-10 | 2015-10-16 | Mohamed Skiba | Composition pharmaceutique pour l'administration par voie nasale de la metopimazine |
| AU2013370966A1 (en) | 2012-12-24 | 2015-06-18 | Neurogastrx, Inc. | Methods for treating GI tract disorders |
| IN2013MU02528A (enExample) | 2013-07-31 | 2015-06-26 | Centaur Pharmaceuticals Private Ltd | |
| WO2015200369A1 (en) | 2014-06-24 | 2015-12-30 | Neurogastrx, Inc. | Prodrugs of metopimazine |
-
2013
- 2013-12-19 AU AU2013370966A patent/AU2013370966A1/en not_active Abandoned
- 2013-12-19 CN CN201380067866.8A patent/CN104884064A/zh active Pending
- 2013-12-19 ES ES13869541T patent/ES2955693T3/es active Active
- 2013-12-19 CA CA2893427A patent/CA2893427C/en active Active
- 2013-12-19 JP JP2015549742A patent/JP6154025B2/ja active Active
- 2013-12-19 CA CA3178035A patent/CA3178035A1/en active Pending
- 2013-12-19 WO PCT/US2013/076733 patent/WO2014105655A1/en not_active Ceased
- 2013-12-19 EP EP13869541.6A patent/EP2934540B1/en active Active
- 2013-12-19 BR BR112015015258A patent/BR112015015258A2/pt not_active IP Right Cessation
-
2014
- 2014-11-26 US US14/555,455 patent/US9132134B2/en active Active
-
2015
- 2015-08-07 US US14/820,885 patent/US9808467B2/en active Active
-
2017
- 2017-05-31 JP JP2017108370A patent/JP6437593B2/ja active Active
- 2017-09-27 US US15/717,765 patent/US20180200258A1/en not_active Abandoned
-
2018
- 2018-11-14 JP JP2018213361A patent/JP2019048848A/ja active Pending
- 2018-12-11 US US16/216,257 patent/US20190314384A1/en not_active Abandoned
-
2020
- 2020-04-30 US US16/862,762 patent/US11147820B2/en active Active
-
2021
- 2021-02-12 JP JP2021021155A patent/JP2021088575A/ja active Pending
- 2021-09-17 US US17/477,830 patent/US20220202826A1/en not_active Abandoned
-
2023
- 2023-06-05 US US18/205,634 patent/US20240058353A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016507500A5 (enExample) | ||
| CA2856646C (en) | Combination treatment of cancer | |
| RU2014109074A (ru) | ИНГИБИТОРЫ ФАННИ-ТОКА (If), ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ В СПОСОБЕ ЛЕЧЕНИЯ И ПРЕДУПРЕЖДЕНИЯ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ У КОШАЧЬИХ | |
| JP2015512406A5 (enExample) | ||
| JP2014526503A5 (enExample) | ||
| AR082150A1 (es) | N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolin-3-carboxamida deuterada, sales y usos de la misma, metodo de tratamiento, mezcla compuestos, composicion farmaceutica, proceso de preparacion, compuesto enriquecido con deuterio | |
| JP2015515985A5 (enExample) | ||
| HUE029677T2 (hu) | Készítmények centrálisan mediált émelygés és hányás kezelésére | |
| JP2018507243A5 (enExample) | ||
| JP2015522630A5 (enExample) | ||
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| JP2013541583A5 (enExample) | ||
| CN110840895A (zh) | 使用维生素b组合物促进胃肠系统动力的方法 | |
| ME02474B (me) | Terapijski režimi | |
| RU2018123718A (ru) | Режимы дозирования мелфлуфена для раковых заболеваний | |
| JP2019218379A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| JPWO2019241442A5 (enExample) | ||
| US11766430B2 (en) | Methods of using a phenoxypropylamine compound to treat pain | |
| JP2017533956A (ja) | 筋肉痛を含む病態の治療のための組合せ | |
| CN104114165B (zh) | 用于治疗憩室病的方法和组合物 | |
| CN109758452A (zh) | 胺类化合物治疗疼痛的医药用途 | |
| TW200831072A (en) | Non-steroidal anti-inflammatory drugs for cough | |
| RU2016144695A (ru) | Комплекс танната ситаглиптина | |
| TWI856977B (zh) | 胺基甲酸酯化合物及包括該化合物之組合於預防、緩解或治療急性壓力症或創傷後壓力症之用途 |